United States: EU Court Confirms European Commission's Decision On Pay-For-Delay Agreements


On 8 September 2016, the General Court of the European Union upheld the European Commission's decision in which the antitrust regulator imposed fines of approximately EUR 150 million on Lundbeck and a number of generic companies for entering into reverse settlement agreements which delayed the entry of cheaper generic versions of a blockbuster antidepressant.

The Commission had first hinted that patent settlement agreements causing delayed generic entry might be problematic in its 2009 report on the Pharmaceutical Sector Inquiry.  

In Depth

The Commission launched a formal antitrust investigation against Lundbeck in January 2010, only six months after publishing the Final Report of the Pharmaceutical Sector Inquiry. The investigation was concluded on 19 June 2013, when the Commission imposed a fine of EUR 93 million on Lundbeck, and fines amounting to EUR 52 million on several generic manufacturers, for breaching Article 101(1) of the Treaty on the Functioning of the European Union (TFEU).

The Commission found that, shortly prior to the expiry of the underlying intellectual property protection, the Danish firm agreed with its generic competitors to delay the market entry of cheaper generic versions of Lundbeck's branded Citalopram, a popular anti-depressant. In return for not entering the market, the generic producers obtained "substantial payments and other inducements" from Lundbeck, often corresponding to the profits that the generics could have expected following entry. In particular, the value transfers took the form of direct lump-sum payments and acquisitions of generic stock for subsequent destruction.

The Commission held that the reverse payment settlement agreements were in violation of Article 101(1) TFEU "by object" and that Lundbeck's reverse payments served to eliminate the generics' incentives to continue their independent efforts to enter the market. Furthermore, the Commission noted that acceptance of the limitations was achieved not by the strength of Lundbeck's patents, but by the transfer of value from Lundbeck to each of the generic companies.

Appeal to the General Court

Lundbeck brought an appeal against the Commission's decision arguing, inter alia, that (i) Lundbeck and the generic companies that were parties to the agreements were not potential competitors under Article 101(1) TFEU, and (ii) the Commission's conclusion that the patent settlement agreements restricted competition by object under Article 101(1) rests on a wrongful application of the established principles on restrictions by object.

In the 8 September 2016 judgment, the General Court dismissed all of Lundbeck's grounds of appeal and upheld the Commission's 2013 decision.

Potential Competition

The General Court held that the Commission had carried out a careful examination of the real, concrete possibilities that the generic companies had of entering the market, and had based its findings on objective evidence. The Court agreed with the Commission's finding that Lundbeck's patents did not necessarily constitute insurmountable barriers for the generic manufacturers which were willing and ready to enter the market, and which had already made considerable investments to do so. This apparent readiness to enter the market, according to the General Court, represented the expression of potential competition.

The Court concluded that, in order to establish the existence of potential competition, it is not necessary to demonstrate with certainty that the generic manufacturers would have entered the market and that that entry would inevitably have been successful, but only that they had real, concrete possibilities in that respect.  

"By Object" Infringement

The General Court also held that the Commission was correct in considering that the very existence of payments from the originator to the generic, and the disproportionate nature of those payments, were relevant factors in establishing whether the agreements constituted restrictions of competition "by object". This is because, through those payments, the originator provided an incentive to the generics not to continue their independent efforts to enter the market. The Court also pointed out that an agreement may be regarded as having a restrictive object even if it does not have the restriction of competition as its sole aim but also pursues other legitimate objectives (such as the settlement of a dispute).

The General Court held that the reverse payment settlement agreements at issue were comparable to market exclusion agreements, which are among the most serious restrictions of competition, and that the exclusion of competitors from the market constitutes an extreme form of market sharing and limitation of production. The Court concluded that such agreements may, by their very nature, be regarded as restricting competition in a sufficiently serious manner as to be classified as a restriction "by object", which by its very nature cannot benefit from the possibility of exemption under Article 101(3) TFEU.

The General Court also found that Lundbeck had failed to demonstrate that these arrangements were needed to protect its intellectual property rights.


Many pharmaceutical companies will find the General Court's judgment difficult to accept. The imposition of a blanket ban on reverse settlement agreements appears to be predicated on the assumption that the only purpose of such settlements is to delay unduly the entry of a generic product and to prolong the exclusivity enjoyed by the originator.

The presumption that a reverse settlement agreement is less competitive than the expected outcome of the litigation that is being settled appears at least controversial. By condemning reverse settlements, the Commission is implying that the generic company would have successfully challenged (i.e., invalidated) the originator's patent rights, and that the settlement is therefore an artificial way of preserving a patent that ought not to confer upon its holder any exclusivities. Given the inherent complexities and uncertainties attached to patent litigation, this is an assumption that should be difficult for an antitrust regulator to make.


The General Court's decision is not final, as recipients of the judgment may still bring an appeal to the Court of Justice questioning the General Court's stance on reverse payment settlements as well as the Court's approach to restriction "by object". Lundbeck already issued a press release stating that it strongly disagrees with the ruling and that it is considering whether to bring an appeal before the Court of Justice.

This judgment will have important implications for the remaining pay-for-delay appeals currently pending in Luxembourg, as well as for the related damages action before the UK Competition Appeal Tribunal.  

Originators and generics wishing to discontinue pending patent litigation should carefully consider the terms and conditions of their settlement agreements, with particular attention given to the overall scope of such agreements and any value transfer that may be construed, where relevant, as an inducement to ensure that a contract party delays or cancels market entry. 

EU Court Confirms European Commission's Decision On Pay-For-Delay Agreements

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions